Massimo Corsaro

VP Global Medical Hematology-Biosimilars Franchise Team Leader @Pfizer. 25+ years in Hemato-oncology. Honored to be here. My opinions are my own. #PFEColleague

[Pfizer Oncology Medical @PfizerOncMed]

In @BloodCancerJnl, read consensus recommendations from an expert panel discussing infection management in patients with #MultipleMyeloma receiving bispecific antibody therapy https://t.co/BAU49WiOnu

[Massimo Corsaro @Massimo_Pfizer]

Please join me virtually to learn from world renowned CML expert Prof Tim Brummendorf @brummendorf #EHA2023 on Wednesday June 14 @ 9:45 CEST as he presents “A case-based approach to CML treatment for newly diagnosed and resistant/intolerant adult patients’https://t.co/YW7hdj1jOY

[Pfizer Oncology Medical @PfizerOncMed]

The study design for the phase 1b/2 MagnetisMM-4 study evaluating BCMA-CD3 bispecific antibody (BsAb)-based regimens for patients with #MultipleMyeloma is being presented at #ASH22 4567 https://t.co/9C2tFd3Yi2

[Pfizer Oncology Medical @PfizerOncMed]

At #ASH22, see a meta-analysis comparing incidence of cytokine release syndrome in two classes of anti-cancer therapy for patients with relapsed/refractory #MultipleMyeloma 4509 https://t.co/dgpFljHuZv

[Massimo Corsaro @Massimo_Pfizer]

Pfizer is currently enrolling clinical studies for patients with advanced hematologic malignancies, such as AML, DLBCL and MM. To learn more about these studies, visit https://t.co/eTpROhnXZS and https://t.co/88VLO7QAYG

[Pfizer Oncology Medical @PfizerOncMed]

At #ASH22, see a US claims study examining all-cause & cancer-related health care resource utilization & costs in pts w/ #AcuteLymphoblasticLeukemia receiving an antibody-drug conjugate vs a bi-specific monoclonal antibody during 1st salvage in R/R 3608 https://t.co/BHV7d0AU4s

[Pfizer Oncology Medical @PfizerOncMed]

See more at #ASH22 about an analysis of a phase 3 trial examining the impact of comorbidities on efficacy and safety of TKIs in patients with newly diagnosed chronic phase #CML 1703
https://t.co/6um8917vvR

[Pfizer Oncology Medical @PfizerOncMed]

At #ASH22, hear our oral presentation on results from the phase 2 MagnetisMM-3 study in triple-class exposed patients with relapsed/refractory #MultipleMyeloma. Read the abstract now.

[Pfizer Oncology Medical @PfizerOncMed]

At #ASH22, don’t miss our oral presentation on results from the ongoing phase 1 MagnetisMM-1 study in patients with relapsed/refractory #MultipleMyeloma. Read the abstract now.

[Pfizer Oncology Medical @PfizerOncMed]

Pfizer supports the mission of @ASH_hematology to foster transformative care, research and education to improve the lives of people living with blood and bone marrow cancers. We’re proud to have 11 presentations at #ASH22.

[Massimo Corsaro @Massimo_Pfizer]

You can also read the article @DanyHabr and I cowrote earlier this year on Pfizer’s #healthequality efforts in #MultipleMyeloma at https://t.co/CjlvNijnXL

[Massimo Corsaro @Massimo_Pfizer]

I am excited to attend #ASH22 & discuss our latest clinical findings from @pfizer with friends and colleagues. Our work continues beyond the 30+ abstracts we have this weekend and we’re dedicated to creating more options for patients in need. Learn more at https://t.co/OaFh99FfhJ

[Pfizer Inc. @pfizer_news]

We're pleased to announce that our investigational treatment for relapsed or refractory #multiplemyeloma was granted U.S. FDA Breakthrough Therapy Designation. MM is an aggressive blood cancer with limited treatment options for these patients. Learn more: https://t.co/eZKoVdgj8T

[Massimo Corsaro @Massimo_Pfizer]

@Pfizer is proud to honor #BloodCancerAwarenessMonth. Watch as my colleagues and I highlight Pfizer's ongoing commitment and never-ending dedication to the 1 million people diagnosed with blood cancer globally each year #PfizerProud #ItsInOurBlood

[Massimo Corsaro @Massimo_Pfizer]

Another day during #BloodCancerAwarenessMonth, another thing to learn: 9/22 is #WCMLD22 as it numerically represents the genetic change of chromosomes 9 and 22—the cause of CML. Thank you @cmlnet for all you do with #PatientAdvocacy and education

[Massimo Corsaro @Massimo_Pfizer]

I recently caught up on some reading and wanted to share this insight from @EHRIntel on a solution to tedious and lengthy data collection processes in point of care research: https://t.co/jnbo1lyjK2. A great example on how we can work smarter not harder in #research

[Massimo Corsaro @Massimo_Pfizer]

#PfizerProud for this data and our continued commitment to CML patients #ItsInOurBlood

[Pfizer Oncology Medical @PfizerOncMed]

Read more about the final 3-year results of a phase 2 study evaluating the efficacy and safety of a BCR-ABL inhibitor in Japanese patients with newly diagnosed chronic phase #ChronicMyeloidLeukemia https://t.co/M5oOXYj47E

[Massimo Corsaro @Massimo_Pfizer]

A jaw dropping read on IPD trial sharing of #oncology drugs after FDA approval--thanks @natanshmodi @AbuhelwaAhmad @RossAMcKinnon and the team at @JAMAOnc for this audit: https://t.co/vcb3iXKecH. We need to improve IPD sharing rates to help current + future oncology #researchers

[Massimo Corsaro @Massimo_Pfizer]

Complimenti per un grande anno @CureTalks + Priya! Your platform continues to further the conversation on #myeloma and other critical diseases. Looking forward to your next 10 years

[Priya Menon @cure_talk]

@CureTalks turns 10 today! We went live this day in 2012 with a talk on #myeloma with @ravivij @grpetersen1 @nvdAB. It has been an incredible journey. Thank you for all the support! @MyelomaTeacher @JackMAiello @MPG61 @yelakbiru (Missing Pat Killingsworth today) #mmsm

[Pfizer Oncology Medical @PfizerOncMed]

Pfizer is proud to announce an Independent Medical Education grant focused on increasing HCP understanding of BCMA-directed therapies in relapsed/refractory #MultipleMyeloma. Read more here: https://t.co/skJmc0Kr1I